\-\ Texto\\:\\ \ \(0\)\
\-\ non\\-contributory\ \(73\)\
\-\ steriods\\ and\\ radiation\\ therapy\ \(0\)\
\-\ three\\ enhancing\\ lesions\\ \\-\\ the\\ largest\\ of\\ which\\ is\\ in\\ the\\ right\\ thalamus\\.\ \(0\)\
\-\ primary\\ cns\\ lymphoma\ \(0\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ \\â\\€\\¢\\ multiple\\ sclerosis\ \(0\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ 62\\ year\\ old\\ previously\\ healthy\\ woman\\ presents\\ with\\ dizziness\\,\\ headache\\ and\\ slurred\\ speech\\.\ \(1\)\
\-\ all\\ of\\ lesions\\ either\\ decreased\\ in\\ size\\ or\\ resolved\\ following\\ high\\ dose\\ steroid\\ administration\\.\\ \\ this\\ why\\ pcnsl\\ is\\ sometimes\\ called\\ the\\ \\"ghost\\ tumor\\"\\ \\-\\ because\\ the\\ lesions\\ can\\ rapidly\\ disappear\\.\\ \\ the\\ yield\\ on\\ tissue\\ biopsy\\ can\\ also\\ drop\\ if\\ the\\ tissue\\ is\\ sampled\\ after\\ a\\ course\\ of\\ steroid\\ therapy\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ steroid\\:\\ 0\\.2623315213581471\ \(0\)\
\-\ lesions\\:\\ 0\\.23446471740536512\ \(0\)\
\-\ pcnsl\\:\\ 0\\.2079559703578075\ \(0\)\
\-\ ghost\\:\\ 0\\.2079559703578075\ \(0\)\
\-\ steriods\\:\\ 0\\.19142009875872185\ \(0\)\
\-\ sampled\\:\\ 0\\.19142009875872185\ \(0\)\
\-\ disappear\\:\\ 0\\.18455709196184128\ \(0\)\
\-\ yield\\:\\ 0\\.1748842271596362\ \(0\)\
\-\ slurred\\:\\ 0\\.16956086551844052\ \(0\)\
\-\ why\\:\\ 0\\.1652113623574311\ \(0\)\
\-\ the\\:\\ 0\\.16292280271565981\ \(0\)\
\-\ lymphoma\\:\\ 0\\.16209356222041846\ \(0\)\
\-\ thalamus\\:\\ 0\\.15737449708036427\ \(0\)\
\-\ therapy\\:\\ 0\\.15637881008256538\ \(0\)\
\-\ drop\\:\\ 0\\.14802185480363333\ \(0\)\
\-\ can\\:\\ 0\\.14282573049438202\ \(0\)\
\-\ tissue\\:\\ 0\\.14277378444689318\ \(0\)\
\-\ speech\\:\\ 0\\.1403662096488581\ \(0\)\
\-\ largest\\:\\ 0\\.13856488486812787\ \(0\)\
\-\ rapidly\\:\\ 0\\.1360947956572553\ \(0\)\
\-\ dizziness\\:\\ 0\\.13281166979643996\ \(0\)\
\-\ 62\\:\\ 0\\.12962611552338868\ \(0\)\
\-\ sometimes\\:\\ 0\\.12735237491023793\ \(0\)\
\-\ cns\\:\\ 0\\.12708281023473153\ \(0\)\
\-\ dose\\:\\ 0\\.12708281023473153\ \(0\)\
\-\ called\\:\\ 0\\.12708281023473153\ \(0\)\
\-\ resolved\\:\\ 0\\.12224687980564279\ \(0\)\
\-\ healthy\\:\\ 0\\.1154386519535034\ \(0\)\
\-\ either\\:\\ 0\\.1125011715271384\ \(0\)\
\-\ is\\:\\ 0\\.11180304293178699\ \(0\)\
\-\ previously\\:\\ 0\\.10924299552387295\ \(0\)\
\-\ administration\\:\\ 0\\.10837086947910274\ \(0\)\
\-\ course\\:\\ 0\\.10051932796659746\ \(0\)\
\-\ sclerosis\\:\\ 0\\.09693006859294416\ \(0\)\
\-\ biopsy\\:\\ 0\\.09539042343725929\ \(0\)\
\-\ because\\:\\ 0\\.09510809801261057\ \(0\)\
\-\ headache\\:\\ 0\\.0938108738062215\ \(0\)\
\-\ size\\:\\ 0\\.09214282434392226\ \(0\)\
\-\ three\\:\\ 0\\.09135059098428668\ \(0\)\
\-\ radiation\\:\\ 0\\.09018093418388293\ \(0\)\
\-\ enhancing\\:\\ 0\\.08524885554405472\ \(0\)\
\-\ decreased\\:\\ 0\\.08429356944312705\ \(0\)\
\-\ primary\\:\\ 0\\.08367732285467383\ \(0\)\
\-\ following\\:\\ 0\\.08163779944480735\ \(0\)\
\-\ all\\:\\ 0\\.08100789565750394\ \(0\)\
\-\ of\\:\\ 0\\.07989343743418804\ \(0\)\
\-\ if\\:\\ 0\\.07906851040196626\ \(0\)\
\-\ high\\:\\ 0\\.07734154679687386\ \(0\)\
\-\ metastatic\\:\\ 0\\.07463557296172284\ \(0\)\
\-\ tumor\\:\\ 0\\.0711801197917966\ \(0\)\
\-\ woman\\:\\ 0\\.07087328315092971\ \(0\)\
\-\ in\\:\\ 0\\.06770684343375849\ \(0\)\
\-\ multiple\\:\\ 0\\.06656191943841586\ \(0\)\
\-\ after\\:\\ 0\\.06601685028046142\ \(0\)\
\-\ presents\\:\\ 0\\.06546369717026508\ \(0\)\
\-\ also\\:\\ 0\\.06401027635404913\ \(0\)\
\-\ which\\:\\ 0\\.061879002848168475\ \(0\)\
\-\ disease\\:\\ 0\\.057123463328316686\ \(0\)\
\-\ and\\:\\ 0\\.056240415983304905\ \(0\)\
\-\ or\\:\\ 0\\.047341394820860715\ \(0\)\
\-\ this\\:\\ 0\\.04676110507387139\ \(0\)\
\-\ right\\:\\ 0\\.045117661843111403\ \(0\)\
\-\ year\\:\\ 0\\.04193858173535908\ \(0\)\
\-\ on\\:\\ 0\\.04109987260108104\ \(0\)\
\-\ old\\:\\ 0\\.04027555586628457\ \(0\)\
\-\ with\\:\\ 0\\.026647057914672475\ \(0\)\
